IL-33 independently induces eosinophilic pericarditis and cardiac dilation ST2 improves cardiac function

Circulation: Heart Failure

Volumn 5, Issue 3, 2012, Pages 366-375

  Abston, Eric D ^a   Barin, Jobert G ^a   Cihakova, Daniela ^a   Bucek, Adriana ^a   Coronado, Michael J ^a   Brandt, Jessica E ^a   Kim, Djahida Bedjajoseph B ^a   Georgakopoulos, Dimitrios ^a   Gabrielson, Kathleen L ^a   Mitzner, Wayne ^a   Fairweather, Delisa ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cytokines; Eosinophils; Idiopathic dilated cardiomyopathy; Inflammation; Myocarditis

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; ISOPRENALINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; RECOMBINANT INTERLEUKIN 33; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN 33, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; COXSACKIE VIRUS B; DIAGNOSTIC TEST ACCURACY STUDY; EOSINOPHILIA; EOSINOPHILIC PERICARDITIS; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE PRESSURE; MALE; MOUSE; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COXSACKIE VIRUS INFECTION; DISEASE MODEL; DRUG EFFECT; GENETICS; HEART; HEART MUSCLE; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOMYOPATHY, DILATED; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; EOSINOPHILIA; HEART; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; PERICARDITIS; RECEPTORS, INTERLEUKIN; RECOMBINANT PROTEINS;

EID: 84864325315     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.963769     Document Type: Article

References (42)

1. O'Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Tex Heart Inst J. 1987;14:268-275.
2. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538.
3. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update. Circulation. 2011;123:e18-e209.
4. Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods. 2007;41:118-122.
5. Afanasyeva M, Wang Y, Kaya Z, Park S, Zilliox MJ, Schofield BH, Hill SL, Rose NR. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol. 2001;159:193-203.
6. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Gatewood SJL, Davis SE, Njoku DB, Rose NR. IFN-protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-1, IL-1, and IL-4 in the heart. Am J Pathol. 2004;165:1883-1894.
7. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
8. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol. 1993;151:1682-1690.
9. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15: 543-562.
10. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103-110.
11. Matsuyama Y, Okazaki H, Hoshino M, Onishi S, Kamata Y, Nagatani K, Nagashima T, Iwamoto M, Yoshio T, Ohto-Ozaki H, Tamemoto H, Komine M, Sekiya H, Tominaga SI, Minota S. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 2010;37:18-25.
12. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105:10913-10918.
13. Xu D, Jiang HR, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, Melendez AJ, Liew FY. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010;184: 2620-2626.
14. Sanada S, Hakuno D, Hiqqins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549.
15. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2:684-691.
16. Georgakopoulos D, Kass DA. Protocols for hemodynamic assessment of transgenic mice in vivo. Methods Mol Biol. 2003;219:233-243.
17. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protocols. 2008;3:1422-1434.
18. Abston ED, Coronado MJ, Bucek A, Bedja D, Shin J, Kim JB, Kim E, Gabrielson KL, Georgakopoulos D, Mitzner W, Fairweather D. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease. Clin Dev Immunol. 2012;2012: 129486.
19. Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol. 1997;272:H1137-H1146.
20. Gyurko R, Kuhlencordt P, Fishman MC, Huang PL. Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J Physiol Heart Circ Physiol. 2000;278:H971-H981.
21. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Rose NR, Fairweather D. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710-6714.
22. Barin JG, Talor MV, Baldeviano GC, Kimura M, Rose NR, Cihakova D. Mechanisms of IFN-regulation of autoimmune myocarditis. Exp Mol Pathol. 2010;89:83-91.
23. Baldeviano GC, Barin JG, Talor MV, Srinivasa S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D. Interleukin-17A is dispensable for myocarditis but essential for progression to dilated cardiomyopathy. Circ Res. 2010;106:1646-1655.
24. Fairweather D, Abston ED, Coronado MJ. Biomarkers of heart failure in myocarditis and dilated cardiomyopathy. In Cihakova D, ed. Myocarditis. Rijeka, Croatia: Intech Open Access Publisher; 2011:323-348. Available from: http://www.intechopen.com/books/myocarditis/biomarkers-ofheart-failure-in- myocarditis-and-dilated-cardiomyopathy.
25. Miller AM, Liew FY. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131:179-186.
26. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res. 2004;95:1140-1153.
27. Lamba S, Abraham WT. Alterations in adrenergic receptor signaling in heart failure. Heart Fail Rev. 2000;5:7-16.
28. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa H, Takeshita A. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res. 2002; 90:959-965.
29. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113:1526-1534.
30. Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, Das A, Hogaboam CM. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010;11:52.
31. Pastorelli L, Garq RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107:8017-8022.
32. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721-726.
33. Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R, Rose NR. IL-12R1 and TLR4 increase IL-1-and IL-18-associated myocarditis and coxsackievirus replication. J Immunol. 2003;170: 4731-4737.
34. Afanasyeva M, Georgakopoulos D, Fairweather D, Caturegli P, Kass DA, Rose NR. Novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-knockout mice. Circulation. 2004; 110:2910-2917.
35. Rezaizadeh H, Sanchez-Ross M, Kaluski E, Klapholz M, Haider B, Gerula C. Acute eosinophilic myocarditis: diagnosis and treatment. Acute Cardiac Care. 2010;12:31-36.
36. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, Korber T, Schneider H, Ince H. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010;99:419-427.
37. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010; 185:3472-3480.
38. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL, Natanson C. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol. 1992;263: H668-H675.
39. Li C, Zienkiewicz J, Hawiger J. Interactive sites in the MyD88 Toll/ interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem. 2005;280:26152-26159.
40. Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Berthonneche C, Pedrazzini T, Berger CT, Dirnhofer S, Matter CM, Penninger JM, Lüscher TF, Eriksson U. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res. 2009;105:912-920.
41. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97: 1382-1391.
42. Liu SJ, Zhou W, Kennedy RH. Suppression of beta-adrenergic responsiveness of L-type Ca2-current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999;276:H141-H148.